¡Ya disponible! Investigación de Telegram 2025 — los principales insights del año 
JAMA (Journal of the American Medical Association)
Ir al canal en Telegram
All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot
Mostrar más📈 Análisis del canal de Telegram JAMA (Journal of the American Medical Association)
El canal JAMA (Journal of the American Medical Association) (@jamaupdates) en el segmento lingüístico de Inglés es un actor destacado. Actualmente la comunidad reúne a 15 169 suscriptores, ocupando la posición 1 626 en la categoría Medicina y el puesto 2 526 en la región EEUU.
📊 Métricas de audiencia y dinámica
Desde su creación el невідомо, el proyecto ha mostrado un crecimiento acelerado, reuniendo a 15 169 suscriptores.
Según los últimos datos del 09 junio, 2026, el canal mantiene una actividad estable. En los últimos 30 días la variación de miembros fue de 543, y en las últimas 24 horas de 9, conservando un alto alcance.
- Estado de verificación: No verificado
- Tasa de interacción (ER): El promedio de interacción de la audiencia es 4.43%. Durante las primeras 24 horas tras publicar, el contenido suele obtener 2.15% de reacciones respecto al total de suscriptores.
- Alcance de las publicaciones: Cada publicación recibe en promedio 671 visualizaciones. En el primer día suele acumular 325 visualizaciones.
- Reacciones e interacción: La audiencia responde de forma activa: el promedio de reacciones por publicación es 1.
- Intereses temáticos: El contenido se centra en temas clave como patient, disease, treatment, drug, guideline.
📝 Descripción y política de contenido
El autor describe el recurso como un espacio para expresar opiniones subjetivas:
“All the latest articles published on JAMA before going in to print
Discussion Group
https://t.me/Medical_Professionals_Forum
Contact us
https://t.me/Contact_Updates_in_Medicine_Bot”
Gracias a la alta frecuencia de actualizaciones (últimos datos recibidos el 10 junio, 2026), el canal mantiene la vigencia y un amplio alcance. La analítica demuestra que la audiencia interactúa activamente con el contenido, lo que lo convierte en un punto de referencia dentro de la categoría Medicina.
15 169
Suscriptores
+924 horas
+1037 días
+54330 días
Carga de datos en curso...
Canales Similares
Nube de Etiquetas
Menciones Entrantes y Salientes
---
---
---
---
---
---
Atraer Suscriptores
junio '26
junio '26
+156
en 0 canales
mayo '26
+584
en 0 canales
Get PRO
abril '26
+437
en 0 canales
Get PRO
marzo '26
+217
en 0 canales
Get PRO
febrero '26
+247
en 0 canales
Get PRO
enero '26
+321
en 0 canales
Get PRO
diciembre '25
+277
en 0 canales
Get PRO
noviembre '25
+366
en 2 canales
Get PRO
octubre '25
+164
en 0 canales
Get PRO
septiembre '25
+12
en 0 canales
Get PRO
agosto '25
+29
en 0 canales
Get PRO
julio '25
+30
en 0 canales
Get PRO
junio '25
+17
en 0 canales
Get PRO
mayo '25
+9
en 0 canales
Get PRO
abril '25
+5
en 0 canales
Get PRO
marzo '25
+17
en 0 canales
Get PRO
febrero '25
+12
en 0 canales
Get PRO
enero '25
+18
en 1 canales
Get PRO
diciembre '24
+237
en 0 canales
Get PRO
noviembre '24
+1 122
en 0 canales
Get PRO
octubre '24
+1 120
en 0 canales
Get PRO
septiembre '24
+1 527
en 1 canales
Get PRO
agosto '24
+1 128
en 1 canales
Get PRO
julio '24
+1 216
en 0 canales
Get PRO
junio '24
+781
en 1 canales
Get PRO
mayo '24
+797
en 1 canales
Get PRO
abril '24
+808
en 1 canales
Get PRO
marzo '24
+821
en 2 canales
Get PRO
febrero '24
+753
en 1 canales
Get PRO
enero '24
+768
en 0 canales
Get PRO
diciembre '23
+716
en 1 canales
Get PRO
noviembre '23
+96
en 1 canales
Get PRO
octubre '23
+86
en 0 canales
Get PRO
septiembre '23
+73
en 0 canales
Get PRO
agosto '23
+90
en 0 canales
Get PRO
julio '23
+107
en 0 canales
Get PRO
junio '23
+105
en 0 canales
Get PRO
mayo '23
+169
en 0 canales
Get PRO
abril '23
+128
en 0 canales
Get PRO
marzo '23
+84
en 0 canales
Get PRO
febrero '23
+75
en 0 canales
Get PRO
enero '23
+71
en 0 canales
Get PRO
diciembre '22
+74
en 0 canales
Get PRO
noviembre '22
+149
en 0 canales
Get PRO
octubre '22
+90
en 0 canales
Get PRO
septiembre '22
+138
en 0 canales
Get PRO
agosto '22
+77
en 0 canales
Get PRO
julio '22
+50
en 0 canales
Get PRO
junio '22
+96
en 0 canales
Get PRO
mayo '22
+75
en 0 canales
Get PRO
abril '22
+80
en 0 canales
Get PRO
marzo '22
+65
en 0 canales
Get PRO
febrero '22
+26
en 0 canales
Get PRO
enero '22
+56
en 0 canales
Get PRO
diciembre '21
+44
en 0 canales
Get PRO
noviembre '21
+39
en 0 canales
Get PRO
octubre '21
+61
en 0 canales
Get PRO
septiembre '21
+66
en 0 canales
Get PRO
agosto '21
+65
en 0 canales
Get PRO
julio '21
+96
en 0 canales
Get PRO
junio '21
+120
en 0 canales
Get PRO
mayo '21
+130
en 0 canales
Get PRO
abril '21
+812
en 0 canales
| Fecha | Crecimiento de Suscriptores | Menciones | Canales | |
| 10 junio | +23 | |||
| 09 junio | +9 | |||
| 08 junio | +8 | |||
| 07 junio | +18 | |||
| 06 junio | +13 | |||
| 05 junio | +25 | |||
| 04 junio | +22 | |||
| 03 junio | +9 | |||
| 02 junio | +19 | |||
| 01 junio | +10 |
Publicaciones del Canal
Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification
https://jamanetwork.com/journals/jamacardiology/fullarticle/2850256
This randomized clinical trial evaluates the progression of coronary artery calcification compared with placebo over a 2-year period.
| 2 | Coronary Artery Calcium Progression—A Useful Outcome in Clinical Trials?
https://jamanetwork.com/journals/jamacardiology/fullarticle/2850257
In this issue of JAMA Cardiology, Vossen et al report the results of a randomized clinical trial investigating whether supplementation with the vitamin K homologue menaquinone-7 (MK-7) at a daily dose of 360 µg would delay progression of coronary artery calcification. Among 180 patients with baseline coronary artery calcium (CAC) scores of 50 to 400 Agatston units (AU), they observed a small but statistically significant slowing of CAC progression, measured as either AU or calcium mass score. | 128 |
| 3 | Cost Offset With Quadruple Therapy for Heart Failure
https://jamanetwork.com/journals/jamacardiology/fullarticle/2850258
This economic evaluation examines Medicare-linked registry data to estimate the 1-year health care cost offset and net cost associated with using quadruple guideline-directed medical therapy after hospitalization for heart failure with reduced ejection fraction. | 122 |
| 4 | Neurological Manifestations in Adult Survivors of Ebola Virus Disease
https://jamanetwork.com/journals/jamaneurology/fullarticle/2850237
This cohort study evaluates the neurological health of adult survivors of Ebola virus disease over the course of a 7-year follow-up. | 207 |
| 5 | High-Dose Intravenous Vitamin C and Mortality and Organ Dysfunction in Severe Burn Injury Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2850391
The objective of this study was to determine whether high-dose intravenous vitamin C improves a composite of 28-day mortality and persistent organ dysfunction in patients with severe burn injury. | 374 |
| 6 | High-Dose Intravenous Vitamin C in Severe Burn Injury
https://jamanetwork.com/journals/jama/fullarticle/2850392
This international randomized clinical trial evaluates the efficacy of high-dose intravenous vitamin C in reducing 28-day mortality and persistent organ dysfunction (dependence on mechanical ventilation, kidney replacement therapy, or vasopressor/inotrope support at day 28) in patients with severe burn injury. | 369 |
| 7 | High-Dose Vitamin C in Burns
https://jamanetwork.com/journals/jama/fullarticle/2850393
In this issue of JAMA, Stoppe and colleagues present the results of an international randomized clinical trial that provides evidence that high-dose intravenous vitamin C does not improve outcomes in patients with large burns. The data from the VICTORY trial even suggest that use of vitamin C in patients with large burns might increase mortality. This well-designed study had strict criteria for stopping based on futility or harm. It is clear that the possibility of vitamin C improving outcomes in major burns is extremely low. | 349 |
| 8 | Personalized Blood Pressure Targeting After Endovascular Therapy for Acute Ischemic Stroke
https://jamanetwork.com/journals/jamaneurology/fullarticle/2850074
This randomized clinical trial evaluates whether a reperfusion-guided systolic blood pressure control strategy improves functional outcomes compared with guideline-recommended management after successful endovascular therapy for acute ischemic stroke. | 630 |
| 9 | Pathology and Genetics in a Global Cohort of Parkinsonian Disorders
https://jamanetwork.com/journals/jamaneurology/fullarticle/2850075
This cross-sectional study investigates how genetic variants and neuropathology are associated with clinical features and diagnostic accuracy in movement disorders. | 603 |
| 10 | Self-Reported Seizure Durations
https://jamanetwork.com/journals/jamaneurology/fullarticle/2850076
This cohort study examines the range of self-reported seizure durations from more than 18 000 children and adults. | 549 |
| 11 | Missing Funding/Support and Role of the Funder Statement
https://jamanetwork.com/journals/jamaneurology/fullarticle/2850077
In the Original Investigation titled “Phenoconversion in Pure Autonomic Failure: A Systematic Review and Meta-Analysis,” published online on May 4, 2026, the Funding/Support and Role of the Funder/Sponsor acknowledgments were missing in the Article Information. The work was funded by a grant from Parkinson’s UK. This information has been added, in addition to the Role of the Funder/Sponsor. This article has been corrected online. | 506 |
| 12 | Survivors of Cyanotic Congenital Heart Disease: A Review
https://jamanetwork.com/journals/jama/fullarticle/2850177
This Review discusses the pathophysiology of cardiovascular complications in adults with cyanotic congenital heart disease after early management and examines late complications and management strategies. | 438 |
| 13 | Evaluating Inflammatory Joint Pain in Older Adults
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2850108
This Clinical Insights discusses inflammatory arthritis in older adults and offers practical guidance. | 456 |
| 14 | Cognition After Postoperative Delirium
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2850109
Postoperative delirium is common in older adults, but some of its long-term consequences remain debated. Its association with adverse outcomes is well established, including longer hospital stays, functional decline, institutionalization, and mortality. A more challenging question is whether delirium itself contributes to later cognitive decline or if it mainly identifies patients who already have frailty, have a health record that is medically complex, and are likely to become ill again. These competing explanations have distinct implications for care, including what we tell patients and families at discharge, how we plan follow-up, and how much emphasis we place on delirium prevention. In this issue of JAMA Internal Medicine, Hshieh et al provide data that help advance this debate. | 477 |
| 15 | Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2850142
This study evaluated whether a once-weekly, 9-mg dose of mazdutide (combined with a reduced calorie diet and increased physical activity) leads to effective and safe weight reduction in Chinese adults with obesity (body mass index [BMI] ≥30) compared with placebo. | 561 |
| 16 | Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity
https://jamanetwork.com/journals/jama/fullarticle/2850143
This randomized clinical trial compares the efficacy and safety of a 9-mg dose of mazdutide vs placebo in Chinese adults with obesity. | 535 |
| 17 | Insulin Costs and Use After the Inflation Reduction Act Out-of-Pocket Cap
https://jamanetwork.com/journals/jama/fullarticle/2850128
This interrupted time series analysis uses Medicare Part D data from January 2021 through December 2023 to measure changes in insulin cost and use after the Inflation Reduction Act $35 cap on out-of-pocket insulin costs, overall and for insulin users with previously high out-of-pocket cost. | 710 |
| 18 | Insulin Cost Caps and Pharmacoequity
https://jamanetwork.com/journals/jama/fullarticle/2850129
Diabetes incidence is rising in the US, with more than 40 million US residents living with this condition. Diabetes morbidity and mortality are unequally distributed, and new diagnoses are higher among American Indian/Alaska Native, Black, and Hispanic adults, compared with White adults. Managing prescription medications is critical to reducing diabetes morbidity, as is controlling risk factors and associated comorbid conditions. However, the cost of pharmacologic therapy has increased substantially, driven in part by the growing use of newer glucose-lowering agents. The high cost of these medications comprises a substantial portion of diabetes-related health care expenditure for individuals with diabetes and may result in restrictive coverage by health plans insuring enrollees with diabetes, further limiting access to care. The out-of-pocket costs faced by patients are particularly burdensome, because patients also face the consequences of adverse downstream outcomes that result from reduced medication adherence due to costs. | 702 |
| 19 | Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases Research Summary
https://jamanetwork.com/journals/jama/fullarticle/2850123
This study evaluated whether finerenone, a nonsteroidal mineralocorticoid receptor antagonist, can slow loss of kidney function in patients with glomerular diseases. | 840 |
| 20 | Finerenone for CKD Due to Glomerular Diseases
https://jamanetwork.com/journals/jama/fullarticle/2850124
This exploratory analysis of a randomized clinical trial evaluates the efficacy and safety of finerenone in reducing chronic kidney disease of participants with glomerular diseases, including disease subtype. | 795 |
